Number Title Principal Investigator(s) Enrolment Status Publication Status Study Description
SASL 46SASL Swiss Cirrhosis Cohort Study (SSciCos)Bernsmeier, Berzigottinot yet recruitingstudy ongoingStudy summary
SASL 45Swiss registry on hepatocellular adenomaMontserrat Fraga recruitingstudy ongoingStudy summary
SASL 44DAA Treatment Failure in Chronic Hepatitis C - The Swiss ExperienceMontserrat Fragano longer recruitingstudy ongoingStudy summary
SASL 43Swiss IgG4 disease cohortM Delgado, Bernrecruitingstudy ongoingStudy summary
SASL 42Autoimmune Idiopathic Disorders in HCV patients: effect of direct Antiviral Agents (DAA)Guido Stirnimann, Giuseppe Murgia, Annalisa Berzigottirecruitingstudy ongoingStudy summary
SASL 40Swiss registry on Primar Sclerosing Cholangitis SWISS PSCJoachim Mertens, Universitätsspital Zürichrecruitingstudy ongoing
SASL 39Swiss registry on Primary Biliary CholangitisBenedetta Terziroli Beretta-Piccoli, Andreas Cerny; Epatocentro Ticino, Luganorecruitingstudy ongoingStudy summary
SASL 38Swiss registry on Autoimmune HepatitisBenedetta Terziroli Beretta-Piccoli, Andreas Cerny; Epatocentro Ticino, Luganorecruitingstudy ongoingStudy summary
SASL 37Swiss Hepatitis B Cohort Study Beat Müllhaupt, Universitätsspital Zürichrecruitingstudy ongoing
SASL 36The health burden of Primary Biliary Cholangitis in SwitzerlandBenedetta Terziroli Beretta-Piccoli, Andreas Cerny; Epatocentro Ticino, Via Soldino 5, 6900 LuganoterminatedPublished:
Clin Rev Allergy Immunol., 2018, 54: 295-306
Study summary
SASL 35 Swiss Liver Venous Thrombosis StudyAndrea De Gottardi, Inselspital Bernrecruitingstudy ongoingStudy summary
SASL 34Therapy of NASH with Vitamin D3Andreas Geierno longer recruiting
Public database
-Study summary
SASL 33Plasma and urine metabolomic after percutaneous thermoablation (RFA) of hepatocellular carcinoma to identify novel biomarkersIsabelle Pache, Lausanneno longer recruitingstudy ongoingStudy summary
SASL 32Non-invasive biomarkers for HCC treated with TACEJean-Francois Dufourrecruitingstudy ongoingStudy summary
SASL 31Prospective evaluation of HepIFN test in patients with chronic hepatitis CMarkus Heimterminated-Study summary
SASL 30SAKK 77/09: A phase I open label/Phase II randomized, double-blind, multicenter study investigating the combination of RAD001 and transArterial ChemoEmbolisation (TACE) with doxorubicin in patients with hepatocellular carcinoma eligible for TACEJean-Francois Dufour, Dieter Köberle, Sylvain Terrazterminated-Study summary
SASL 29SAKK 77/08: Sorafenib alone or in combination with everolimus in patients with unresectable hepatocellular carcinoma. A multicenter phase II trial.Dieter Köberle, Jean-Francois Dufourterminated-Study summary
SASL 28A randomized open label study evaluating the efficacy of continuous telbivudine versus lamivudine in patients with HBeAg-negative Chronic Hepatitis B who had previously achieved an undetectable viral load during 24 weeks of telbivudine therapyMarkus Heim, Darius Moradpourterminated-Study summary
SASL 27EuroWilsonDarius Moradpour, Isabelle Pache, Michela Schaeppiterminated
Public database
SASL 26SAKK 77/07: External beam radiotherapy for unresectable hepatocellular carcinoma. A phase I/II trial.PD Dr. med. Ilja Ciernik (Bellinzona), Dr. med. Diana Naehrig (Basel), Prof. Stephan Bodis (Aarau), PD Dr. med. Luca Cozzi (Bellinzona)terminated-
SASL 25TransArterial ChemoEmbolisation (TACE) with doxorubicin incombination with systemic administration of sorafenib for patients with hepatocellular carcinoma.Prof. J.-F. Dufour (Bern), Prof. M. Borner (Bern), Prof. D. Candinas (Bern)terminatedPublished:
Oncologist, 2010, 15:1198-204:
Study summary
SASL 24Prospektive, offene, randomisierte, kontrollierte Therapiestudie zur Wirksamkeit und Verträglichkeit einer Ther. mit PegInterferon-alfa2a + serumspiegeladaptierter Ribavirindosis vs. PegInterferon-alfa2a + gewichtsadaptierter Ribavirindosis bei Pat. mit nicht vorbehandelter chronischer Hepatitis CFelix Stickel (Bern)terminatedPublished:
Am J Gastroenterol., 2013, 108: 1176-8
Study summary
SASL 23Protocol SAKK 77/06, SASL 23: Continuous sunitinib treatment in patients with unresectable hepatocellular carcinoma. A multi-center phase II trial D. Köberle (St.Gallen), M. Montemurro (CHUV Lausanne), M. Borner (Inselspital Bern), P. E. Majno (HUG Genève)terminated
Public database
-Study summary
SASL 22A Pilot Single-Arm, Uncontrolled Study of Treatment with Pegylated Interferon-Alpha2a, Ribavirin and Insulin Sensitizer Pioglitazone of Insulin Resistance (with the Exception of Diabetes) in Hepatitis C Virus Infection (The INSPIRED HCV Study) F. Negroterminated
Public database
Journal of Hepatology, 2008, 49: 295-298
Study summary
SASL 21Prospective evaluation of non-invasive fibrosis markers in patients with hepatitis CJ.Reichenterminated-
SASL 20Treatment with rosiglitazone (Avandia) of patients suffering from non-alcoholic steatohepatitis (NASH). A randomized, plazebo-controlled, double-blinded studyJ.F.Dufourterminated-
SASL 19Prospective randomized controlled multicenter trial comparing transarterial chemoembolization (TACE) versus TACE plus radio frequency thermoablation for the treatment of hepatocellular carcinomas in patients on the waiting list for liver transplantationP.Majno, M.H.Heim, A.Denysterminated-Study summary
SASL 18Treatment of acute hepatitis c with pegylated interferon alpha-2b: correlation between hcv rna kinetics and immunological responseF.NegroterminatedPublished:
Journal of Hepatology, 2005, 42: 323-328
SASL 17Ribavirin / pegasys treatment of recurrent hepatitis C after liver transplantF.Negroterminated
Public database
Transplant Infectious Disease , 2009, 11: 33-39
SASL 16Molecular pathogenesis of cholestatic liver disease: analysis of gene polymorphisms in patients with familial or drug-induced cholestasis or intrahepatic cholestasis of pregnancyG.Kullak-UblickterminatedPublished:
Pharmacogenetics, 2004, 14: 91
SASL 15Treatment with 40 kd branched-peg-interferon alfa-2a and ribavirin of interferon-naive hepatitis C patients with advanced fibrosis or cirrhosis B.Helbling. E.L.RennerterminatedPublished:
Journal of Viral Hepatitis, 2006, 13: 76
SASL 14Treatment with 12 kD PEG-Interferon alfa-2b and ribavirin of interferon-naive patients with chronic hepatitis C and up to moderate fibrosiB.Meyer-WyssterminatedPublished:
Journal of Viral Hepatitis, 2006, 13: 457
SASL 12Treatment with alpha-tocopherol and ursodeoxycholic acid of patients with non-alcoholic steatohepatitis (NASH)B.Müllhauptterminated-
SASL 11Treatment with alpha-tocopherol and ursodeoxycholic acid of patients with non-alcoholic steatohepatitis (NASH)J.-F.DufourterminatedPublished:
Clinical Gastroenterology and Hepatology, 2006, 4: 1537-1543
SASL 10Ribavirin and interferon combination in chronic hepatitis c patients not responding to interferon-alpha monotherapyE.L.Rennerterminated-
SASL 9Reinduction therapy with interferon alpha-2b and ribavirin in interferon monotherapy relapse patients with chronic hepatitis CJ. BorovickaterminatedPublished:
Swiss Medical Weekly, 2003, 133: 455-460
SASL 8Interferon alpha +/- amantadine in interferon naive patients with chronic hepatitis CB.Helbling, E.L.RennerterminatedPublished:
Hepatology, 2002, 35: 447